Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nikord
- Development stage
- Preclinical
- Lead developer
- Kian Immune Cell Company
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Oral
01
Overview
Nikord is a preclinical cord blood-derived natural killer (NK) cell therapy being developed by Kian Immune Cell Company for the treatment of solid tumors. The therapy utilizes allogeneic NK cells isolated and expanded from umbilical cord blood. Its mechanism of action involves the direct destruction of tumor cells through NK cell-mediated cytotoxicity and the subsequent activation of a broader innate immune response. As an "off-the-shelf" product, Nikord aims to provide a readily available cellular immunotherapy option for patients with various oncology-related diseases.
- Brand names
- Nikord
- Other names
- NiKord
Beyond the preview
Go deeper on Nikord.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nikord.